Beigene Ltd

KY

Health Care

130.94 ₽

Current price

Hold
130.94 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    483 / 1361

  • Position in country

    65 / 99

  • Return on Assets, %

    -14.9

    -40.3

  • Net income margin, %

    -58

    -180

  • EBITDA margin, %

    -56.8

    -168.2

  • Debt to Equity, %

    25

    3.2

  • Intangible assets and goodwill, %

    0.9

    0.2

  • Revenue CAGR 3Y, %

    99.6

    12.5

  • Total Equity change 1Y, %

    -19.4

    -9

  • Revenue Y, % chg

    73.6

    0

  • P/BV

    3.8

    1.8

  • P/S

    6

    10.3

  • EV/S

    5.4

    7.5

  • EV/EBITDA

    -14.8

    -1.6

  • Average Analyst recommendation

    Buy

    Buy

  • Average upside forecasts, %

    98.1

    131.1

  • Expected dividend per share

    0

    0

Get an analytical review of this company

Competitors

Ranks

  • Vertex Pharmaceuticals Inc

    00%

  • CSL Ltd

    00%

  • Regeneron Pharmaceuticals Inc

    00%

  • Gilead Sciences Inc

    00%

  • Seagen Inc

    00%

  • Amgen Inc

    00%

  • Beigene Ltd

    00%

  • Moderna Inc

    00%

  • AbbVie Inc

    00%

  • Polaris Group

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    Cayman Islands

  • Sector

    Health Care

  • Industry group

    Pharmaceuticals, Biotechnology & Life Sciences

  • Industry

    Biotechnology

  • Sub-sector

    Health Care

  • Capitalization (millions of $)

    15584.7

  • Ticker

    BGNE.OQ

  • ISIN

    US07725L1026

  • IPO date

    2016-02-03

  • Availability on Russian exchanges

    Yes

  • Reporting for

    2024-02-26

  • Date fact. publication of reports

    2023-12-31

Company Description

Beigene Ltd is a biotechnology company in the commercial stage. The Company focuses on research and development (R&D), production and commercialization of innovative drugs. The Company has three products approved for listing, including Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290). The Company also has eight products in clinical stage, including BGB-283, BGB-A333, BGB-A425, BGB-A1217, BGB-A445, BGB-11417, BGB-10188 and BGB-15025. The Company's business covers China, the United States, Australia, Canada, Singapore, Russia, Brazil, Europe and other countries and regions.

A step towards better analytics

  • find the best promotions through the Screener
  • keep an eye on stock valuation
  • download detailed reports

and much more after free registration

Registration

More convenient from your phone? Download: